Report cover image

Global Prediabetes Market Growth, Size, Trends Analysis - By Drug Class, By Age Group - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published May 21, 2025
Length 250 Pages
SKU # SPER20187017

Description

Global Prediabetes Market Introduction and Overview

According to SPER market research, ‘Global Prediabetes Market Size- By Drug Class, By Age Group – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Prediabetes Market is predicted to reach 1021.93 million by 2034 with a CAGR of 11.19%.

Prediabetes is a medical condition in which blood sugar levels are elevated above the normal range but not high enough to be classified as type 2 diabetes. Fasting blood glucose levels typically range from 100 to 125 mg/dL in individuals with prediabetes. This condition suggests early issues with blood sugar regulation, often resulting from insulin resistance.

Restraints:

The global prediabetes market faces a number of obstacles that limit its overall growth. A key issue is the high rate of underdiagnosis, as prediabetes often lacks noticeable symptoms, leaving many individuals unaware they are affected. This is further exacerbated by low public awareness and inadequate routine screening, especially in low-resource and developing regions.

Scope of the report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Drug Class, By Age Group

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Novo Nordisk A/S, Valbiotis, RESVERLOGIX, Caelus Health, Scimar, Boston Pharmaceuticals, APHAIA PHARMA AG, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc.

Global Prediabetes Market Segmentation:

By Drug Class: Based on the Drug Class, Global Prediabetes Market is segmented as; Diguanide, Thiazolidinediones, Glucagon-like peptide-1 agonists (GLP-1), SGLT2 inhibitors, DPP-4 inhibitors, Others.

By Age Group: Based on the Age Group, Global Prediabetes Market is segmented as; {(Children (12-18 years), Adults (18-49), Elderly (50+).

By Region:

This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

250 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Prediabetes Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Prediabetes Market
7. Global Prediabetes Market, By Drug Class, (USD Million) 2021-2034
7.1. Diguanide
7.2. Thiazolidinediones
7.3. Glucagon-like peptide-1 agonists (GLP-1)
7.4. SGLT2 inhibitors
7.5. DPP-4 inhibitors
7.6. Others
8. Global Prediabetes Market, By Age Group, (USD Million) 2021-2034
8.1. Children (12-18 years)
8.2. Adults (18-49)
8.3. Elderly (50+)
9. Global Prediabetes Market, (USD Million) 2021-2034
9.1. Global Prediabetes Market Size and Market Share
10. Global Prediabetes Market, By Region, 2021-2034 (USD Million)
10.1. Asia-Pacific
10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada
10.4.2. Mexico
10.4.3. United States
10.5. Latin America
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America
11. Company Profile
11.1. Novo Nordisk A/S
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Valbiotis
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. RESVERLOGIX
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Caelus Health
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Scimar
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Boston Pharmaceuticals
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. APHAIA PHARMA AG
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. AstraZeneca
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Bristol-Myers Squibb Company
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. Pfizer Inc.
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us